<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607694</url>
  </required_header>
  <id_info>
    <org_study_id>DAHANCA 35</org_study_id>
    <nct_id>NCT04607694</nct_id>
  </id_info>
  <brief_title>DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer</brief_title>
  <acronym>DAHANCA 35</acronym>
  <official_title>DAHANCA 35: A Randomized Trial of Proton Versus Photon Radiotherapy for the Treatment of Head-neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Head and Neck Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Head and Neck Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with squamous cell carcinoma of the pharynx or larynx and an anticipated benefit of&#xD;
      proton radiotherapy in reducing the risk of late dysphagia or xerostomia are randomized to&#xD;
      proton or photon radiotherapy (2:1)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DAHANCA 35 is two parallel conducted, but separate randomized studies, within the same trial&#xD;
      (DAHANCA 35D and DAHANCA 35X) by the Danish Head-Neck Cancer Study Group (DAHANCA). In&#xD;
      patients with squamous cell carcinoma of the pharynx or larynx planned for primary&#xD;
      radiotherapy a proton and a photon doseplan is prepared. If proton radiotherapy reduces the&#xD;
      anticipated absolute risk of dysphagia &gt;= grade 2 (DAHANCA scale, DAHANCA 35D) or severe&#xD;
      xerostomia &gt;= grade 4 (EORTC Head-Neck 35, DAHANCA 35X) more than 5%, the patient is&#xD;
      randomised to either proton therapy or photon therapy, 2:1. The anticipated risk of&#xD;
      xerostomia and dysphagia is estimated using Normal-Tissue Complication Models (NTCP). Patient&#xD;
      are analysed according to the primary endpoint (dysphagia and/or xerostomia) after which they&#xD;
      were enrolled. DAHANCA 35D is expected to enroll 360 patients and DAHANCA 35X 240 patients&#xD;
      (in total 600 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysphagia &gt;= grade 2</measure>
    <time_frame>Six months after end of radiotherapy</time_frame>
    <description>The rate of observer-reported dysphagia &gt;= grade 2 measured by the DAHANCA late toxicity score (grade 0-4, with 0 being best)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Xerostomia = grade 4</measure>
    <time_frame>Six months after end of radiotherapy</time_frame>
    <description>The rate of patient-reported xerostomia measured by the EORTC Quality of life questionnaire (QLQ) Head-Neck (HN) 35 (grade 1-4, with 1 being best)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loco-regional tumor control</measure>
    <time_frame>Up to five years after end of radiotherapy</time_frame>
    <description>Time to event of local-regional failure, from date of randomization to the date of first documented loco-regional failure. Rates are estimated by the Kaplan-Meier method. Interim analyses after 100, 200 and 300 patients. Will not be reported before the primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to five years after end of radiotherapy</time_frame>
    <description>From date of randomisation to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with disease-free survival</measure>
    <time_frame>Up to five years after end of radiotherapy</time_frame>
    <description>From date of randomization to date of death (all causes), loco-regional failure or distant failure, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>Up to five years after end of radiotherapy</time_frame>
    <description>From date of randomization to date of death (by loco-regional or distant failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>From the beginning of and up to two months after end of radiotherapy</time_frame>
    <description>DAHANCA acute toxicity score (grade 0-4, 0 being best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>From two months to five years after end of radiotherapy</time_frame>
    <description>DAHANCA late toxicity score (grade 0-4, 0 being best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-Head-Neck 35</measure>
    <time_frame>Up to ten years after end of radiotherapy</time_frame>
    <description>Swallowing and social-eating scale and specific HN35 items related to eating and pain (grade 1-4, 1 being best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC C30</measure>
    <time_frame>Up to ten years after end of radiotherapy</time_frame>
    <description>Specific C30 items related to fatigue, nausea and vomiting (grade 1-4, 1 being best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD Anderson Dysphagia Index</measure>
    <time_frame>Up to ten years after end of radiotherapy</time_frame>
    <description>MD Anderson Dysphagia Index (MDADI) (grade 1-5, 1 being best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Five Dimension Scale (EQ-5D)</measure>
    <time_frame>Up to ten years after end of radiotherapy</time_frame>
    <description>Quality-adjusted life-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite time corrected toxicity score (CTCT)</measure>
    <time_frame>Up to five years after end of radiotherapy</time_frame>
    <description>The sum of the time corrected dysphagia score and the time corrected xerostomia score normalised to maximum score across all days using EORTC QLQ-Head-Neck 35. The measure is unit-less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified barium swallowing</measure>
    <time_frame>One year after end of radiotherapy</time_frame>
    <description>Functional swallowing test - DIGEST scale (grade 0-4, 0 being best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulated whole-mouth salivary flow</measure>
    <time_frame>Up to five years after end of radiotherapy</time_frame>
    <description>Stimulated whole-mouth salivary flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Head-and-neck Cancer</condition>
  <arm_group>
    <arm_group_label>Proton radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photon radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiotherapy</intervention_name>
    <description>Proton radiotherapy</description>
    <arm_group_label>Proton radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon radiotherapy</intervention_name>
    <description>Photon radiotherapy</description>
    <arm_group_label>Photon radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven squamous cell carcinoma of the pharynx or larynx&#xD;
             planned for primary radiotherapy with curative intent&#xD;
&#xD;
          -  A predicted clinical significant reduction in the risk of any of the two primary&#xD;
             endpoints (&gt;= grade 2 observer-rated dysphagia or grade 4 patient-reported xerostomia)&#xD;
             after proton therapy compared to photon therapy based on comparison of the individual&#xD;
             patient dose plans&#xD;
&#xD;
          -  No current or earlier malignancies, which may influence treatment, evaluation or&#xD;
             outcome of the head-neck cancer&#xD;
&#xD;
          -  Informed consent as required by law&#xD;
&#xD;
          -  Above 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with cancers of the glottic larynx (stage I/II), skull base, sino-nasal area,&#xD;
             unknown primary tumor and prior malignancies.&#xD;
&#xD;
          -  Patients with contraindications for proton therapy. Per October 2020, this includes&#xD;
             pacemakers, implanted defibrillators and tracheostomy&#xD;
&#xD;
          -  Inability to attend full course of radiotherapy or follow-up visits in the outpatient&#xD;
             clinic&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Previous radiotherapy of the head and neck&#xD;
&#xD;
          -  Previous surgery for the primary cancer with curative intent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeppe Friborg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Head-Neck Cancer Group (DAHANCA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeppe Friborg, MD, PhD</last_name>
    <phone>+45 35458189</phone>
    <email>jeppe.friborg@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kenneth Jensen, MD, PhD</last_name>
    <phone>+45 78456400</phone>
    <email>kennjens@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Andersen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin S Nielsen, MSc</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Eriksen, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jørgen BB Petersen, MSc</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Danish Center for Particle Therapy</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Jensen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elo Andersen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeppe Friborg, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Bob Smulders, MSc</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Næstved Hospital</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Farhadi, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Eva Samsøe, MSc, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørgen Johansen, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Christian R Hansen, MSc</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proton radiotherapy</keyword>
  <keyword>DAHANCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

